Exact Mass: 521.271
Exact Mass Matches: 521.271
Found 500 metabolites which its exact mass value is equals to given mass value 521.271
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Morphiceptin
D002491 - Central Nervous System Agents > D000697 - Central Nervous System Stimulants > D003292 - Convulsants D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D018377 - Neurotransmitter Agents > D018847 - Opioid Peptides Morphiceptin is a peptide isolated from beta-casein. [HMDB] D018377 - Neurotransmitter Agents > D004723 - Endorphins Morphiceptin is a peptide isolated from beta-casein. Morphiceptin is a potent and specific agonist for morphine (μ) receptors. Morphiceptin, as a synthetic peptide, is the amide of a fragment of the milk protein β-casein. Morphiceptin has morphinelike activities and is highly specific for morphine (μ) receptors but not for enkephalin (?) receptors[1]. Morphiceptin is a potent and specific agonist for morphine (μ) receptors. Morphiceptin, as a synthetic peptide, is the amide of a fragment of the milk protein β-casein. Morphiceptin has morphinelike activities and is highly specific for morphine (μ) receptors but not for enkephalin (?) receptors[1].
LysoPS(18:2(9Z,12Z)/0:0)
LysoPS(18:2(9Z,12Z)/0:0) is a lysophosphatidylserine. It is a glycerophospholipid in which a phosphorylserine moiety occupies a glycerol substitution site. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic. However, it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Lysophosphatidylserines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. LysoPS(18:2(9Z,12Z)/0:0), in particular, consists of one chain of linoleic acid at the C-1 position.
Batrachotoxinin A 20-alpha-benzoate
D009676 - Noxae > D011042 - Poisons > D014688 - Venoms
Thienorphine
D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids
3alpha-[4-(beta-D-glucopyranosyloxy)-3-methoxy-5-(3-methyl-2-butenyl)benzoyloxy]tropane|merresectine D beta-D-glucoside
Phe Asn Ile Glu
Phe Lys Val Glu
Ala Glu Phe Arg
Ala Glu Arg Phe
Ala Phe Glu Arg
Ala Phe Arg Glu
Ala Phe Val Trp
Ala Phe Trp Val
Ala Arg Glu Phe
Ala Arg Phe Glu
Ala Val Phe Trp
Ala Val Trp Phe
Ala Trp Phe Val
Ala Trp Val Phe
Asp Phe Ile Lys
Asp Phe Ile Gln
Asp Phe Lys Ile
Asp Phe Lys Leu
Asp Phe Leu Lys
Asp Phe Leu Gln
Asp Phe Gln Ile
Asp Phe Gln Leu
Asp Ile Phe Lys
Asp Ile Phe Gln
Asp Ile Lys Phe
Asp Ile Gln Phe
Asp Lys Phe Ile
Asp Lys Phe Leu
Asp Lys Ile Phe
Asp Lys Leu Phe
Asp Lys Pro Tyr
Asp Lys Tyr Pro
Asp Leu Phe Lys
Asp Leu Phe Gln
Asp Leu Lys Phe
Asp Leu Gln Phe
Asp Pro Lys Tyr
Asp Pro Tyr Lys
Asp Gln Phe Ile
Asp Gln Phe Leu
Asp Gln Ile Phe
Asp Gln Leu Phe
Asp Tyr Lys Pro
Asp Tyr Pro Lys
Glu Ala Phe Arg
Glu Ala Arg Phe
Glu Phe Ala Arg
Glu Phe Ile Asn
Glu Phe Lys Val
Glu Phe Leu Asn
Glu Phe Asn Ile
Glu Phe Asn Leu
Glu Phe Gln Val
Glu Phe Arg Ala
Glu Phe Val Lys
Glu Phe Val Gln
Glu Ile Phe Asn
Glu Ile Asn Phe
Glu Lys Phe Val
Glu Lys Val Phe
Glu Arg Ala Phe
Glu Arg Phe Ala
Glu Val Phe Lys
Glu Val Lys Phe
Phe Ala Glu Arg
Phe Ala Arg Glu
Phe Ala Val Trp
Phe Ala Trp Val
Phe Asp Ile Lys
Phe Asp Lys Ile
Phe Asp Lys Leu
Phe Asp Leu Lys
Phe Glu Ala Arg
Phe Glu Lys Val
Phe Glu Arg Ala
Phe Glu Val Lys
Phe Gly Ile Trp
Phe Gly Leu Trp
Phe Gly Trp Ile
Phe Gly Trp Leu
Phe Ile Asp Lys
Phe Ile Gly Trp
Phe Ile Lys Asp
Phe Ile Trp Gly
Phe Lys Asp Ile
Phe Lys Asp Leu
Phe Lys Glu Val
Phe Lys Ile Asp
Phe Lys Leu Asp
Phe Lys Met Pro
Phe Lys Asn Asn
Phe Lys Pro Met
Phe Leu Asp Lys
Phe Leu Gly Trp
Phe Leu Lys Asp
Phe Leu Trp Gly
Phe Met Lys Pro
Phe Met Pro Lys
Phe Asn Lys Asn
Phe Asn Asn Lys
Phe Pro Lys Met
Phe Pro Met Lys
Phe Arg Ala Glu
Phe Arg Glu Ala
Phe Val Ala Trp
Phe Val Glu Lys
Phe Val Lys Glu
Phe Val Trp Ala
Phe Trp Ala Val
Phe Trp Gly Ile
Phe Trp Gly Leu
Phe Trp Ile Gly
Phe Trp Leu Gly
Phe Trp Val Ala
Gly Phe Ile Trp
Gly Phe Leu Trp
Gly Phe Trp Ile
Gly Phe Trp Leu
Gly Ile Phe Trp
Gly Ile Trp Phe
Gly Leu Phe Trp
Gly Leu Trp Phe
Gly Trp Phe Ile
Gly Trp Phe Leu
Gly Trp Ile Phe
Gly Trp Leu Phe
His His Lys Thr
His His Thr Lys
His Lys His Thr
His Lys Thr His
His Thr His Lys
His Thr Lys His
Ile Asp Phe Lys
Ile Asp Lys Phe
Ile Phe Asp Lys
Ile Phe Gly Trp
Ile Phe Lys Asp
Ile Phe Trp Gly
Ile Gly Phe Trp
Ile Gly Trp Phe
Ile Ile Asn Tyr
Ile Ile Tyr Asn
Ile Lys Asp Phe
Ile Lys Phe Asp
Ile Lys Met Met
Ile Leu Asn Tyr
Ile Leu Tyr Asn
Ile Met Lys Met
Ile Met Met Lys
Ile Asn Ile Tyr
Ile Asn Leu Tyr
Ile Asn Tyr Ile
Ile Asn Tyr Leu
Ile Gln Val Tyr
Ile Gln Tyr Val
Ile Val Gln Tyr
Ile Val Tyr Gln
Ile Trp Phe Gly
Ile Trp Gly Phe
Ile Tyr Ile Asn
Ile Tyr Leu Asn
Ile Tyr Asn Ile
Ile Tyr Asn Leu
Ile Tyr Gln Val
Ile Tyr Val Gln
Lys Asp Phe Ile
Lys Asp Phe Leu
Lys Asp Ile Phe
Lys Asp Leu Phe
Lys Glu Phe Val
Lys Glu Val Phe
Lys Phe Asp Ile
Lys Phe Asp Leu
Lys Phe Glu Val
Lys Phe Ile Asp
Lys Phe Leu Asp
Lys Phe Met Pro
Lys Phe Asn Asn
Lys Phe Pro Met
Lys Phe Val Glu
Lys His His Thr
Lys His Thr His
Lys Ile Asp Phe
Lys Ile Phe Asp
Lys Ile Met Met
Lys Leu Asp Phe
Lys Leu Phe Asp
Lys Leu Met Met
Lys Met Phe Pro
Lys Met Ile Met
Lys Met Leu Met
Lys Met Met Ile
Lys Met Met Leu
Lys Met Pro Phe
Lys Asn Phe Asn
Lys Asn Asn Phe
Lys Pro Phe Met
Lys Pro Met Phe
Lys Thr His His
Lys Val Glu Phe
Lys Val Phe Glu
Leu Asp Phe Lys
Leu Asp Lys Phe
Leu Phe Asp Lys
Leu Phe Gly Trp
Leu Phe Lys Asp
Leu Phe Trp Gly
Leu Gly Phe Trp
Leu Gly Trp Phe
Leu Ile Asn Tyr
Leu Ile Tyr Asn
Leu Lys Asp Phe
Leu Lys Phe Asp
Leu Lys Met Met
Leu Leu Asn Tyr
Leu Leu Tyr Asn
Leu Met Lys Met
Leu Met Met Lys
Leu Asn Ile Tyr
Leu Asn Leu Tyr
Leu Asn Tyr Ile
Leu Asn Tyr Leu
Leu Gln Val Tyr
Leu Gln Tyr Val
Leu Val Gln Tyr
Leu Val Tyr Gln
Leu Trp Phe Gly
Leu Trp Gly Phe
Leu Tyr Ile Asn
Leu Tyr Leu Asn
Leu Tyr Asn Ile
Leu Tyr Asn Leu
Leu Tyr Gln Val
Leu Tyr Val Gln
Met Phe Lys Pro
Met Phe Pro Lys
Met Ile Lys Met
Met Ile Met Lys
Met Lys Phe Pro
Met Lys Ile Met
Met Lys Leu Met
Met Lys Met Ile
Met Lys Met Leu
Met Lys Pro Phe
Met Leu Lys Met
Met Leu Met Lys
Met Met Ile Lys
Met Met Lys Ile
Met Met Lys Leu
Met Met Leu Lys
Met Pro Phe Lys
Met Pro Lys Phe
Asn Phe Lys Asn
Asn Phe Asn Lys
Asn Ile Ile Tyr
Asn Ile Leu Tyr
Asn Ile Tyr Ile
Asn Ile Tyr Leu
Asn Lys Phe Asn
Asn Lys Asn Phe
Asn Leu Ile Tyr
Asn Leu Leu Tyr
Asn Leu Tyr Ile
Asn Leu Tyr Leu
Asn Asn Phe Lys
Asn Asn Lys Phe
Asn Tyr Ile Ile
Asn Tyr Ile Leu
Asn Tyr Leu Ile
Asn Tyr Leu Leu
Pro Phe Lys Met
Pro Phe Met Lys
Pro Lys Phe Met
Pro Lys Met Phe
Pro Met Phe Lys
Pro Met Lys Phe
Pro Arg Ser Tyr
Pro Arg Tyr Ser
Pro Ser Arg Tyr
Pro Ser Tyr Arg
Pro Tyr Arg Ser
Pro Tyr Ser Arg
Gln Asp Ile Phe
Gln Asp Leu Phe
Gln Glu Val Phe
Gln Phe Asp Ile
Gln Phe Asp Leu
Gln Phe Glu Val
Gln Phe Ile Asp
Gln Phe Leu Asp
Gln Phe Val Glu
Gln Ile Asp Phe
Gln Ile Phe Asp
Gln Ile Val Tyr
Gln Ile Tyr Val
Gln Leu Asp Phe
Gln Leu Phe Asp
Gln Leu Val Tyr
Gln Leu Tyr Val
Gln Val Glu Phe
Gln Val Phe Glu
Gln Val Ile Tyr
Gln Val Leu Tyr
Gln Val Tyr Ile
Gln Val Tyr Leu
Gln Tyr Ile Val
Gln Tyr Leu Val
Gln Tyr Val Ile
Gln Tyr Val Leu
Arg Ala Glu Phe
Arg Ala Phe Glu
Arg Glu Ala Phe
Arg Glu Phe Ala
Arg Phe Ala Glu
Arg Phe Glu Ala
Arg Pro Ser Tyr
Arg Pro Tyr Ser
Arg Ser Pro Tyr
Arg Ser Tyr Pro
Arg Tyr Pro Ser
Arg Tyr Ser Pro
Ser Pro Arg Tyr
Ser Pro Tyr Arg
Ser Arg Pro Tyr
Ser Arg Tyr Pro
Ser Tyr Pro Arg
Ser Tyr Arg Pro
Thr His His Lys
Thr His Lys His
Thr Lys His His
Val Ala Phe Trp
Val Ala Trp Phe
Val Glu Phe Lys
Val Glu Phe Gln
Val Glu Lys Phe
Val Glu Gln Phe
Val Phe Ala Trp
Val Phe Glu Lys
Val Phe Glu Gln
Val Phe Lys Glu
Val Phe Gln Glu
Val Phe Trp Ala
Val Ile Gln Tyr
Val Ile Tyr Gln
Val Lys Glu Phe
Val Lys Phe Glu
Val Leu Gln Tyr
Val Leu Tyr Gln
Val Gln Glu Phe
Val Gln Phe Glu
Val Gln Ile Tyr
Val Gln Leu Tyr
Val Gln Tyr Ile
Val Gln Tyr Leu
Val Trp Ala Phe
Val Trp Phe Ala
Val Tyr Ile Gln
Val Tyr Leu Gln
Val Tyr Gln Ile
Val Tyr Gln Leu
Trp Ala Phe Val
Trp Ala Val Phe
Trp Phe Ala Val
Trp Phe Gly Ile
Trp Phe Gly Leu
Trp Phe Ile Gly
Trp Phe Leu Gly
Trp Phe Val Ala
Trp Gly Phe Ile
Trp Gly Phe Leu
Trp Gly Ile Phe
Trp Gly Leu Phe
Trp Ile Phe Gly
Trp Ile Gly Phe
Trp Leu Phe Gly
Trp Leu Gly Phe
Trp Val Ala Phe
Trp Val Phe Ala
Tyr Asp Lys Pro
Tyr Asp Pro Lys
Tyr Ile Ile Asn
Tyr Ile Leu Asn
Tyr Ile Asn Ile
Tyr Ile Asn Leu
Tyr Ile Gln Val
Tyr Ile Val Gln
Tyr Lys Asp Pro
Tyr Lys Pro Asp
Tyr Leu Ile Asn
Tyr Leu Leu Asn
Tyr Leu Asn Ile
Tyr Leu Asn Leu
Tyr Leu Gln Val
Tyr Leu Val Gln
Tyr Asn Ile Ile
Tyr Asn Ile Leu
Tyr Asn Leu Ile
Tyr Asn Leu Leu
Tyr Pro Asp Lys
Tyr Pro Lys Asp
Tyr Pro Arg Ser
Tyr Pro Ser Arg
Tyr Gln Ile Val
Tyr Gln Leu Val
Tyr Gln Val Ile
Tyr Gln Val Leu
Tyr Arg Pro Ser
Tyr Arg Ser Pro
Tyr Ser Pro Arg
Tyr Ser Arg Pro
Tyr Val Ile Gln
Tyr Val Leu Gln
Tyr Val Gln Ile
Tyr Val Gln Leu
Deproceptin
Morphiceptin is a potent and specific agonist for morphine (μ) receptors. Morphiceptin, as a synthetic peptide, is the amide of a fragment of the milk protein β-casein. Morphiceptin has morphinelike activities and is highly specific for morphine (μ) receptors but not for enkephalin (?) receptors[1]. Morphiceptin is a potent and specific agonist for morphine (μ) receptors. Morphiceptin, as a synthetic peptide, is the amide of a fragment of the milk protein β-casein. Morphiceptin has morphinelike activities and is highly specific for morphine (μ) receptors but not for enkephalin (?) receptors[1].
Tauroursodeoxycholic acid sodium salt
Tauroursodeoxycholate (Tauroursodeoxycholic acid; TUDCA) sodium is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK.
Sodium taurochenodeoxycholate
D005765 - Gastrointestinal Agents > D002756 - Cholagogues and Choleretics D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D000890 - Anti-Infective Agents > D000998 - Antiviral Agents D005765 - Gastrointestinal Agents > D002793 - Cholic Acids Taurochenodeoxycholic acid (12-Deoxycholyltaurine) sodium is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid sodium induces apoptosis and shows obvious anti-inflammatory and immune regulation properties[1][2].
Sodium Taurodeoxycholate
Taurodeoxycholate sodium salt is a bile salt-related anionic detergent used for isolation of membrane proteins including inner mitochondrial membrane proteins. Taurodeoxycholate (TDCA) inhibits various inflammatory responses[1] [2][3].
2-C22:0-alpha,omega-dicaboxyl-lysophosphatidic acid
8-[1-(1,3-Benzodioxol-5-yl)-3-(1-piperidinyl)propyl]-5,7-dimethoxy-4-pentyl-1-benzopyran-2-one
N-[[(2S,3S)-8-[2-(2-fluorophenyl)ethynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
propan-2-yl N-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
[(1R)-1-[(3-fluorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]-(4-oxanyl)methanone
[(1S)-1-[(3-fluorophenyl)methyl]-1-(hydroxymethyl)-7-methoxy-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]-(4-oxanyl)methanone
N-[[(2S,3R)-8-[2-(2-fluorophenyl)ethynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
N-[(2R,4aR,12aS)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide
N-[(2S,4aS,12aR)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide
N-[(2S,4aR,12aS)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]pyrazine-2-carboxamide
N-[[(2R,3R)-8-[2-(2-fluorophenyl)ethynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
N-[[(2R,3R)-8-[2-(2-fluorophenyl)ethynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
N-[[(2S,3S)-8-[2-(2-fluorophenyl)ethynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
N-[[(2R,3S)-8-[2-(2-fluorophenyl)ethynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
N-[[(2S,3R)-8-[2-(2-fluorophenyl)ethynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
N-[[(2R,3S)-8-[2-(2-fluorophenyl)ethynyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylcyclohexanecarboxamide
N-[(2S,4aR,12aR)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide
N-[(2S,4aS,12aS)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]pyrazine-2-carboxamide
N-[[(2S,3R)-8-(1-cyclohexenyl)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-1,3-benzodioxole-5-carboxamide
propan-2-yl N-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
propan-2-yl N-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
propan-2-yl N-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
propan-2-yl N-[[(10S,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
propan-2-yl N-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
propan-2-yl N-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
N-[(2R,4aR,12aR)-2-[2-(cyclohexylmethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-2-pyrazinecarboxamide
2-amino-3-[hydroxy-[2-hydroxy-3-[(9Z,12Z)-octadeca-9,12-dienoyl]oxypropoxy]phosphoryl]oxypropanoic acid
Morphiceptin
D002491 - Central Nervous System Agents > D000697 - Central Nervous System Stimulants > D003292 - Convulsants D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D018377 - Neurotransmitter Agents > D018847 - Opioid Peptides D018377 - Neurotransmitter Agents > D004723 - Endorphins Morphiceptin is a potent and specific agonist for morphine (μ) receptors. Morphiceptin, as a synthetic peptide, is the amide of a fragment of the milk protein β-casein. Morphiceptin has morphinelike activities and is highly specific for morphine (μ) receptors but not for enkephalin (?) receptors[1]. Morphiceptin is a potent and specific agonist for morphine (μ) receptors. Morphiceptin, as a synthetic peptide, is the amide of a fragment of the milk protein β-casein. Morphiceptin has morphinelike activities and is highly specific for morphine (μ) receptors but not for enkephalin (?) receptors[1].
1-(9Z,12Z-octadecadienoyl)-glycero-3-phosphoserine
Exarafenib
Exarafenib (RAF/KIN_2787) is an orally-available, selective pan-RAF inhibitor. Exarafenib is effective in RAF-dependent cancers, including all classes of BRAF alterations. Exarafenib suppresses MAPK signaling in RAF-dependent melanoma cell lines. Exarafenib has anticancer activity[1][2].